Format

Send to

Choose Destination
Cancer Nurs. 2018 Sep/Oct;41(5):424-430. doi: 10.1097/NCC.0000000000000524.

Sociodemographic Predictors of Anal Cancer Screening and Follow-up in Human Immunodeficiency Virus-Infected Individuals.

Author information

1
Author Affiliation: Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, Georgia.

Abstract

BACKGROUND:

Anal cancer in the United States is generally rare; however, human immunodeficiency virus (HIV)-infected individuals are 28 times more likely to be given a diagnosis of anal cancer than the general population.

OBJECTIVE:

The aim of this study was to examine the rates and sociodemographic predictors of anal cancer screening and follow-up anoscopy in a sample of HIV-infected individuals.

METHODS:

Data for this study (n = 200) were derived from a retrospective chart review of randomly selected HIV-infected individuals. Data analyses included Pearson's correlation coefficient statistic to examine bivariate associations and logistic regression modeling for prediction of anal Papanicolaou test screening and follow-up anoscopy.

RESULTS:

Screening rates and follow-up after an abnormal anal Pap test were low. Women were less likely to be screened for anal cancer (odds ratio [OR], 0.244; P = .007). Men who have sex with men were almost 4 times more likely to be screened for anal cancer (OR, 3.7; P = .02). Men who have sex with men were 6 times more likely to have follow-up after an abnormal anal Pap test compared with heterosexual men or women of any sexual orientation (OR, 6.88; P = .002).

CONCLUSIONS:

High-risk groups for anal cancer should be targeted for preventative measures as part of a cancer prevention plan to decrease the personal and clinical burden associated with anal cancer.

IMPLICATIONS FOR PRACTICE:

Cancer prevention is a multistep process that requires screening and follow-up efforts, where healthcare providers play a vital role in these efforts. Findings from this study can inform strategies to improve screening and follow-up rates in HIV-infected individuals.

PMID:
28723723
PMCID:
PMC5767552
[Available on 2019-09-01]
DOI:
10.1097/NCC.0000000000000524

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center